The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose.

Chang AM, Jakobsen G, Sturis J, Smith MJ, Bloem CJ, An B, Galecki A, Halter JB

Diabetes1 Jul 2003Cited by 157 (Europe PMC)

PMID12829647DOI10.2337/diabetes.52.7.1786PepBankPUB-12829647

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In subjects with type 2 diabetes, a single dose of NN2211 (liraglutide) increased insulin levels compared with placebo.
In plain wordsIn people with type 2 diabetes, one dose of liraglutide raised insulin levels more than placebo during a glucose test.
Peptide
Liraglutide
Outcome
IncreaseInsulin levels during glucose infusion
Study
n = 10
Comparator
Placebo
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
7.5 micro g/kg single dose · single doseAs given in this study (human).
Source sentences
Summary
NN2211, in comparison with placebo, increased insulin and C-peptide levels
2 context sentences(design, population, supporting numbers)
Summary · context
We tested NN2211, a long-acting GLP-1 derivative, in 10 subjects with type 2 diabetes (means +/- SD: age 63 +/- 8 years, BMI 30.1 +/- 4.2 kg/m(2), HbA(1c) 6.5 +/- 0.8%) in a randomized, double-blind, placebo-controlled, crossover study.
Summary · context
A single injection (7.5 micro g/kg) of NN2211 or placebo was administered 9 h before the study. beta-cell sensitivity was assessed by a graded glucose infusion protocol, with glucose levels matched over the 5-12 mmol/l range.
Report a problemFND-1282964701
02HumanRandomized controlled trialEfficacy outcome
In subjects with type 2 diabetes, a single dose of NN2211 (liraglutide) increased C-peptide levels compared with placebo.
In plain wordsIn people with type 2 diabetes, one dose of liraglutide raised C-peptide levels more than placebo during a glucose test.
Peptide
Liraglutide
Outcome
IncreaseC-peptide levels during glucose infusion
Study
n = 10
Comparator
Placebo
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
7.5 micro g/kg single dose · single doseAs given in this study (human).
Source sentences
Summary
NN2211, in comparison with placebo, increased insulin and C-peptide levels
2 context sentences(design, population, supporting numbers)
Summary · context
We tested NN2211, a long-acting GLP-1 derivative, in 10 subjects with type 2 diabetes (means +/- SD: age 63 +/- 8 years, BMI 30.1 +/- 4.2 kg/m(2), HbA(1c) 6.5 +/- 0.8%) in a randomized, double-blind, placebo-controlled, crossover study.
Summary · context
A single injection (7.5 micro g/kg) of NN2211 or placebo was administered 9 h before the study. beta-cell sensitivity was assessed by a graded glucose infusion protocol, with glucose levels matched over the 5-12 mmol/l range.
Report a problemFND-1282964702
03HumanRandomized controlled trialEfficacy outcome
In subjects with type 2 diabetes, a single dose of NN2211 (liraglutide) increased the insulin secretion rate AUC compared with placebo.
In plain wordsIn people with type 2 diabetes, one dose of liraglutide increased insulin secretion more than placebo.
Peptide
Liraglutide
Outcome
IncreaseInsulin secretion rate AUC
Study
n = 10
Comparator
Placebo
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
7.5 micro g/kg single dose · single doseAs given in this study (human).
Source sentences
Summary
the ISR area under the curve (AUC) (1,130 +/- 150 vs. 668 +/- 106 pmol/kg; P < 0.001)
2 context sentences(design, population, supporting numbers)
Summary · context
We tested NN2211, a long-acting GLP-1 derivative, in 10 subjects with type 2 diabetes (means +/- SD: age 63 +/- 8 years, BMI 30.1 +/- 4.2 kg/m(2), HbA(1c) 6.5 +/- 0.8%) in a randomized, double-blind, placebo-controlled, crossover study.
Summary · context
A single injection (7.5 micro g/kg) of NN2211 or placebo was administered 9 h before the study. beta-cell sensitivity was assessed by a graded glucose infusion protocol, with glucose levels matched over the 5-12 mmol/l range.
Report a problemFND-1282964703
04HumanRandomized controlled trialEfficacy outcome
In subjects with type 2 diabetes, a single dose of NN2211 (liraglutide) increased the slope of insulin secretion rate versus plasma glucose compared with placebo.
In plain wordsIn people with type 2 diabetes, one dose of liraglutide made insulin release respond more to blood sugar than placebo.
Peptide
Liraglutide
Outcome
IncreaseSlope of insulin secretion rate versus plasma glucose
Study
n = 10
Comparator
Placebo
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
7.5 micro g/kg single dose · single doseAs given in this study (human).
Measurements
Slope of ISR versus plasma glucose
1.26 pmol x l[min(-1) x mmol(-1) x kg(-1)]
NN2211
Source sentences
Summary
and the slope of ISR versus plasma glucose (1.26 +/- 0.36 vs. 0.54 +/- 0.18 pmol x l[min(-1) x mmol(-1) x kg(-1)]; P < 0.014)
2 context sentences(design, population, supporting numbers)
Summary · context
We tested NN2211, a long-acting GLP-1 derivative, in 10 subjects with type 2 diabetes (means +/- SD: age 63 +/- 8 years, BMI 30.1 +/- 4.2 kg/m(2), HbA(1c) 6.5 +/- 0.8%) in a randomized, double-blind, placebo-controlled, crossover study.
Summary · context
A single injection (7.5 micro g/kg) of NN2211 or placebo was administered 9 h before the study. beta-cell sensitivity was assessed by a graded glucose infusion protocol, with glucose levels matched over the 5-12 mmol/l range.
Report a problemFND-1282964704
05HumanRandomized controlled trialEfficacy outcome
In subjects with type 2 diabetes, insulin secretion rate AUC after NN2211 (liraglutide) was similar to that of nondiabetic control subjects.
In plain wordsIn people with type 2 diabetes, insulin release after one liraglutide dose was similar to that of people without diabetes.
Peptide
Liraglutide
Outcome
No significant changeInsulin secretion rate AUC compared with nondiabetic controls
Study
n = 10
Comparator
Nondiabetic volunteers
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
7.5 micro g/kg single dose · single doseAs given in this study (human).
Source sentences
Summary
with values similar to those of nondiabetic control subjects (ISR AUC 1,206 +/- 99; slope of ISR versus plasma glucose, 1.44 +/- 0.18).
2 context sentences(design, population, supporting numbers)
Summary · context
We tested NN2211, a long-acting GLP-1 derivative, in 10 subjects with type 2 diabetes (means +/- SD: age 63 +/- 8 years, BMI 30.1 +/- 4.2 kg/m(2), HbA(1c) 6.5 +/- 0.8%) in a randomized, double-blind, placebo-controlled, crossover study.
Summary · context
A single injection (7.5 micro g/kg) of NN2211 or placebo was administered 9 h before the study. beta-cell sensitivity was assessed by a graded glucose infusion protocol, with glucose levels matched over the 5-12 mmol/l range.
Report a problemFND-1282964705
06HumanRandomized controlled trialEfficacy outcome
In subjects with type 2 diabetes, the slope of insulin secretion rate versus plasma glucose after NN2211 (liraglutide) was similar to that of nondiabetic control subjects.
In plain wordsIn people with type 2 diabetes, insulin release responded to blood sugar after one liraglutide dose much as in people without diabetes.
Peptide
Liraglutide
Outcome
No significant changeSlope of insulin secretion rate versus plasma glucose compared with nondiabetic controls
Study
n = 10
Comparator
Nondiabetic volunteers
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
7.5 micro g/kg single dose · single doseAs given in this study (human).
Source sentences
Summary
with values similar to those of nondiabetic control subjects (ISR AUC 1,206 +/- 99; slope of ISR versus plasma glucose, 1.44 +/- 0.18).
2 context sentences(design, population, supporting numbers)
Summary · context
We tested NN2211, a long-acting GLP-1 derivative, in 10 subjects with type 2 diabetes (means +/- SD: age 63 +/- 8 years, BMI 30.1 +/- 4.2 kg/m(2), HbA(1c) 6.5 +/- 0.8%) in a randomized, double-blind, placebo-controlled, crossover study.
Summary · context
A single injection (7.5 micro g/kg) of NN2211 or placebo was administered 9 h before the study. beta-cell sensitivity was assessed by a graded glucose infusion protocol, with glucose levels matched over the 5-12 mmol/l range.
Report a problemFND-1282964706

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 1NCT01511185

Effect of Liraglutide on the Beta-cell Responsiveness in Subjects With Type 2 Diabetes Compared to a Healthy Control Group

Novo Nordisk A/Sn = 20Feb 2001 to Oct 2001

Diabetes · Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 26 Jan 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.